As of May 18
| -0.06 / -0.53%|
The 6 analysts offering 12-month price forecasts for Neogenomics Inc have a median target of 11.00, with a high estimate of 13.00 and a low estimate of 11.00. The median estimate represents a -2.14% decrease from the last price of 11.24.
The current consensus among 7 polled investment analysts is to Buy stock in Neogenomics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.